Skip to main content
Neoplasia (New York, N.Y.) logoLink to Neoplasia (New York, N.Y.)
. 2016 Dec 12;18(12):808–809. doi: 10.1016/j.neo.2016.10.005

Corrigendum to “A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non–Small Cell Lung Cancer Cells” [Neoplasia 18 (2016) 199-212]

Chi-Wei Chen *,, Ming-Hsi Wu , Yi-Fan Chen *,, Tsai-Yi Yen , Yi-Wen Lin , Shu-Hsin Chao , Satishkumar Tala †,1, Tung-Hu Tsai , Tsann-Long Su , Te-Chang Lee *,†,§,
PMCID: PMC5156521  PMID: 27978996

The authors regret to have mistakenly placed the figure of body weight change in mice treated with different agents in PC9 cells (Figure 6A, right) with that of PC9/gef B4 cells (Figure 6B, right) during the art work. The corrected Figure 6 was attached below. The authors would like to apologize for any inconvenience caused.

Figure 6.

Fig. 6

Antitumor activity of BO-1978 in EGFR mutant NSCLC xenografts. Aliquots of 5 × 106 PC9 (A), PC9/gef B4 (B), H1650 (C), and H1975 (D) cells were subcutaneously implanted in nude mice. When tumor sizes reached approximately 100 mm3, the mice were treated with vehicle, BO-1978 (40 mg/kg, daily for 5 consecutive days), gefitinib (10 mg/kg, daily for 5 consecutive days), BO-1978 + gefitinib, or cisplatin (6 mg/kg, three times every 4 days). The tumor volumes and body weights were monitored at the indicated times.


Articles from Neoplasia (New York, N.Y.) are provided here courtesy of Neoplasia Press

RESOURCES